$ANAB

ANAPTYSBIO, INC

CIK:0001370053|SEC Filings

Consolidated Statements of Operations and Comprehensive Loss (unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2026	Mar. 31, 2025
Income Statement [Abstract]
Revenue from Contract with Customer, Product and Service [Extensible Enumeration]	Collaboration Revenue [Member]	Collaboration Revenue [Member]
Collaboration revenue	$ 25,556	$ 27,771
Operating expenses:
Research and development	33,991	41,180
General and administrative	26,202	14,130
Total operating expenses	60,193	55,310
Loss from operations	(34,637)	(27,539)
Other income (expense), net:
Interest income	2,653	4,413
Non-cash interest expense for the sale of future royalties	(20,859)	(18,061)
Other (expense) income, net	(1)	1,902
Total other expense, net	(18,207)	(11,746)
Loss before income taxes	(52,844)	(39,285)
Provision for income taxes	(40)	(44)
Net loss	(52,884)	(39,329)
Other comprehensive loss:
Unrealized loss on available for sale securities	(122)	(144)
Comprehensive loss	$ (53,006)	$ (39,473)
Net loss per common share:
Basic (in dollars per share)	$ (1.84)	$ (1.28)
Diluted (in dollars per share)	$ (1.84)	$ (1.28)
Weighted-average number of shares outstanding:
Basic (in shares)	28,691	30,644
Diluted (in shares)	28,691	30,644

Consolidated Statements of Cash Flows (unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2026	Mar. 31, 2025
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (52,884)	$ (39,329)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	130	146
Stock-based compensation	14,218	9,170
Accretion/amortization of investments, net	(8)	(1,667)
Amortization of right-of-use assets – operating	480	460
Non-cash interest expense for sale of future royalties	20,859	18,061
Changes in operating assets and liabilities:
Receivables from collaborative partners	8,103	22,881
Prepaid expenses and other assets	1,501	530
Accounts payable and other liabilities	(17,819)	(24,034)
Deferred income	0	3,544
Operating lease liabilities	(499)	(462)
Net cash used in operating activities	(25,919)	(10,700)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of investments	0	(122,547)
Sales and maturities of investments	35,000	137,429
Purchases of property and equipment	(17)	(35)
Net cash provided by investing activities	34,983	14,847
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of common stock	14,021	290
Repurchase and retirements of common stock	0	(4,424)
Payment for net share settlement of equity awards	0	(1,451)
Principal repayment of liability for sale of future royalties	(12,812)	(23,005)
Net cash provided by (used in) financing activities	1,209	(28,590)
Net increase (decrease) in cash and cash equivalents	10,273	(24,443)
Cash and cash equivalents, beginning of period	238,196	123,080
Cash and cash equivalents, end of period	248,469	98,637
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION
Interest portion of repayment for sale of future royalties	20,833	18,100
State income taxes paid	40	5
Non-cash investing and financing activities:
Amounts accrued for property and equipment	23	11
Amounts accrued for repurchase of common stock	0	959
Receivable related to issuance of common stock, upon exercise of stock options	$ 304	$ 0

Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2026	Dec. 31, 2025
Current assets:
Cash and cash equivalents	$ 248,469	$ 238,196
Receivables from collaborative partners	25,747	33,850
Short-term investments	37,986	73,442
Prepaid expenses and other current assets	3,907	4,762
Total current assets	316,109	350,250
Property and equipment, net	1,280	1,370
Operating lease right-of-use assets	12,039	12,519
Other long-term assets	256	256
Total assets	329,684	364,395
Current liabilities:
Accounts payable	7,517	3,871
Accrued expenses	32,065	32,674
Current portion of operating lease liability	2,120	2,080
Total current liabilities	41,702	38,625
Liability related to sale of future royalties	263,742	276,528
Operating lease liability, net of current portion	11,493	12,032
Stockholders’ equity:
Preferred stock, $0.001 par value, 10,000 shares authorized and no shares, issued or outstanding at March 31, 2026 and December 31, 2025, respectively	0	0
Common stock, $0.001 par value, 500,000 shares authorized, 29,031 shares and 28,019 shares issued and outstanding at March 31, 2026 and December 31, 2025, respectively	29	28
Additional paid in capital	838,307	809,765
Accumulated other comprehensive loss	(146)	(24)
Accumulated deficit	(825,443)	(772,559)
Total stockholders’ equity	12,747	37,210
Total liabilities and stockholders’ equity	$ 329,684	$ 364,395